Avid Bioservices Inc (CDMO)

[freethemice]

You can't really compare this with anything else. The number of patients involved is way too small.
Also, as the abstract shows the prior treatments received by the enrolled patients varies quite a bit.
That makes any possible comparison difficult. If this was a first-line trial it would be easier.
The point of this phase I trial is to see if the combination of paclitxel and bavi has activity in
HER2-negative MBC, and is safe. Both of which seem to be true so far.